1 |
Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: Results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(suppl. 3):S74-81.
|
2 |
Raftery EB, Lahiri A, Hughes LO, et al. A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. Eur Heart J 1993;14(suppl. B):35-9.
DOI
|
3 |
Markham A, Plosker GL, Goa KL. Nicorandil: An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000;60(4):955-74.
DOI
|
4 |
Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011;71(9):1105-19.
DOI
|
5 |
Cross HR. Trimetazidine for stable angina pectoris. Expert Opin on Pharmacother 2001;2(5):857-75.
DOI
|
6 |
Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: Some insights on its role in heart failure and peripheral artery disease. Drugs 2014;74(9):971-80.
DOI
|
7 |
Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: An overview. Eur Heart J 1993;14(suppl. B):48-52.
|
8 |
Sasaki J, Saeki Y, Kawasaki K, et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease. Cardiovac Drugs Ther 1992;6(5):471-4.
DOI
|
9 |
Wagner G. Selected issues from an overview on nicorandil: Tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol 1992;20(suppl. 3):S86-92.
DOI
|
10 |
Krumenacker M, Roland E. Clinical profile of nicorandil: An overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20(suppl. 3):S93-102.
|
11 |
Dunn N, Freemantle S, Pearce G, et al. Safety profile of nicorandil - Prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999;8(3):197-205.
DOI
|
12 |
Terai H, Yamanishi H, Shimahara M. Nicorandil-induced tongue ulceration with or without fungal infection. Odontology 2012;100(1):100-3.
DOI
|
13 |
Scully C, Azul AM, Crighton A, et al. Nicorandil can induce severe oral ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(2):189-93.
DOI
|
14 |
Egred M. Nicorandil-associated ulcerations. Eur J Gastroenterol Hepatol 2007;19(5):395-8.
DOI
|
15 |
Salim F, Joshi A, Hopkins C. Ulceration of the nasal dorsum: a rare cause? J Laryngol Otology 2014;128(3):289-91.
DOI
|
16 |
Gayet JL, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovas Dis 2011;104(10):536-44.
DOI
|
17 |
Fraunfelder FW, Fraunfelder FT. Conjunctival and corneal ulceration associated with nicorandil. Cutan Ocul Toxicol 2014;33(2):120-1.
DOI
|
18 |
Trechot F, Batta B, Petitpain N, et al. A case of nicorandil-induced unilateral corneal ulceration. Int Wound J 2014;11(3):238-9.
DOI
|
19 |
Campolmi N, Guy C, Cinotti E, et al. Corneal perforation: Another side effect of nicorandil. Cutan Ocul Toxicol 2014;33(2):96-8.
DOI
|
20 |
Trechot P, Petitpain N, Guy C, et al. Nicorandil: From ulcer to fistula into adjacent organs. Int Wound J 2013;10(2):210-3.
DOI
|
21 |
Onay-Besikci A, Özkan SA. Trimetazidine revisited: A comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovas Ther 2008;26(2):147-65.
DOI
|
22 |
The Korean-English Medical Terminology, 5th Edition, Korean Medical Association. Available from http://term.kma.org/. Accessed April 14, 2016.
|
23 |
Lehmann G, Reiniger G, Beyerle A, et al. Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 1998;31(1):25-30.
DOI
|
24 |
Lehmann G, Reiniger G, Beyerle A, et al. Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure. Eur J Clin Pharmacol 1995;48(2):109-14.
DOI
|
25 |
Falase BA, Bajaj BS, Wall TJ, et al. Nicorandil-induced peripheral vasodilatation during cardiopulmonary bypass. Ann Thorac Surg 1999;67(4):1158-9.
DOI
|
26 |
Bricaud H, Brottier L, Barat JL, et al. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drugs Ther 1990;4 Suppl 4:861-5.
DOI
|
27 |
Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11(3):207-12.
DOI
|
28 |
Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: A subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20(9):1447-54.
DOI
|
29 |
Bertel O, Noll G. Additional molsidomine in refractory unstable angina pectoris. Cardiovasc Drugs Ther 1988;2(1):107-11.
DOI
|
30 |
Makolkin VI, Osadchiy KK. Trimetazidine modified release in the treatment of stable angina: TRIUMPH Study. Clin Drug Investig 2004;24(12):731-8.
DOI
|
31 |
Palaniappan M, Selvarajan S, George M, et al. Pattern of adverse drug reactions reported with cardiovascular drugs in a tertiary care teaching hospital. J Clin Diagn Res 2015;9(11):FC01-4.
|
32 |
Toquero L, Briggs CD, Bassuini MM, et al. Anal ulceration associated with nicorandil: Case series and review of the literature. Colorectal Disease 2006;8(8):717-20.
DOI
|
33 |
Kapoor S. Nicorandil and its associated gastrointestinal side effects. Pacing Clin Electrophysiol 2013;36(5):662.
DOI
|
34 |
Baker RP, Al-Kubati W, Atuf M, et al. Nicorandil-induced severe perianal ulceration. Tech Coloproctol 2007;11(4):343-5.
DOI
|
35 |
Yap T, Philippou P, Perry M, et al. Nicorandil-induced penile ulcerations: A case series. BJU Int 2011;107(2):268-71.
DOI
|
36 |
McDaid J, Reichl C, Hamzah I, et al. Diverticular fistulation is associated with nicorandil usage. Ann R Coll Surg Engl 2010;92(6):463-5.
DOI
|
37 |
Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4(4):1075-88.
DOI
|
38 |
Balakumar P, Kavitha M, Nanditha S. Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated. Pharmacol Res 2015;102:81-9.
DOI
|
39 |
Shapey IM, Agbamu D, Newall N, et al. Nicorandil-associated ulceration of the gastrointestinal tract: side effects requiring surgical intervention. Int J of Colorectal Dis 2015;30(8):1143-5.
DOI
|
40 |
Overview of Korean healthcare system based on the Korea Healthcare Panel (2008-2012). Available from https://www.khp.re.kr:444/ver_2/04_study/study01.jsp. Accessed March 25, 2016.
|
41 |
Vital Statistics in 2014 on Cause of Death. Available from http://kostat.go.kr/portal/korea/kor_nw/2/6/2/index.board?bmode=read&aSeq=348539. Accessed April 14, 2016.
|
42 |
The average life expectancy (0 years life expectancy) and healthy life. Available from http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=2758. Accessed March 25, 2016.
|
43 |
Mortality trends by cause of death. Available from http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=1012. Accessed March 25, 2016.
|
44 |
Reden J. Molsidomine. Blood Vessels 1990;27(2-5):282-94.
|
45 |
Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91(2):161-5.
DOI
|
46 |
Shlyakhto EV, Almazov VVA, Nifontov EM, et al. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002;2(2):119-24.
DOI
|
47 |
Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther 1990;4(suppl. 4):853-9.
DOI
|
48 |
McClellan KJ, Plosker GL. Trimetazidine: A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999;58(1):143-57.
DOI
|
49 |
Marti Masso JF, Marti I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005;60(4):419-22.
DOI
|
50 |
Marti Masso JF. Trimetazidine-induced parkinsonism. Neurologia 2004;19(7):392-5.
|
51 |
Masmoudi K, Masson H, Gras V, et al. Extrapyramidal adverse drug reactions associated with trimetazidine: A series of 21 cases. Fundam Clin Pharmacol 2012;26(2):198-203.
DOI
|
52 |
Messin R, Dubois C, Famaey JP. Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities. Adv Ther 2008;25(11):1200-14.
DOI
|
53 |
Messin R, Carreer-Bruhwyler F, Dubois C, et al. Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: Double-blind and open-label studies. Adv Ther 2006;23(1):107-30.
DOI
|
54 |
Beaufils P, Kolsky H, Haiat R, et al. The influence of molsidomine on infarct size: An acute post-infarction pilot study with 303 patients. Cardiovasc Drugs Ther 1988;2(1):127-32.
DOI
|
55 |
Balakumaran K, Hugenholtz PG, Tijssen JGP, et al. Molsidomine, an effective long-acting anti-anginal drug. Eur Heart J 1983;4(9):655-61.
DOI
|
56 |
Nishimura M, Tokoro T, Nishida M, et al. Oral Nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: A randomized trial. Am J Kidney Dis 2009;54(2):307-17.
DOI
|
57 |
Blanc P, Aouifi A, Bouvier H, et al. Safety of oral nicorandil before coronary artery bypass graft surgery. Br J Anaesth 2001;87(6):848-54.
DOI
|
58 |
Wolf DL, Hearron AE, Metzler CM, et al. The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers. Eur J Clin Pharmacol 1993;45(5):437-43.
DOI
|
59 |
Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and antiischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;20(suppl. 3):S67-73.
DOI
|